Neos Therapeutics

Neos Therapeutics, Inc. is a specialty pharmaceutical company with a late-stage pipeline of innovative extended release products for the treatment of ADHD. Neos has submitted an NDA for its methylphenidate XR-ODT drug candidate for ADHD medication based on its patented XR-ODT technology. Neos’ XR-ODT and XR-Liquid product candidates provide patient-friendly dosage forms for patients who have difficulty swallowing tablets or capsules and can benefit from extended- release formulations.